Страница 1 от 2224 резултата
Combining anticancer drugs with different mechanisms of action has the potential to enhance antitumor effect. CPT-11 (Camptosar, irinotecan), a topoisomerase I inhibitor, has been shown to be highly effective in the treatment of a variety of cancers. However, its clinical usage is often complicated
OBJECTIVE
An antitumor camptothecin derivative CPT-11 has proven a broad spectrum of solid tumor malignancy, but its severe diarrhea has often limited its more widespread use. We have demonstrated from a rat model that intestinal beta-glucuronidase may play a key role in the development of
The cancer treatment-related diarrhea caused by acute graft-versus-host disease (GVHD) and chemotherapeutic agents, particularly fluoropyrimidines and irinotecan, significantly affects patient morbidity and mortality. The mechanisms causing cancer treatment-related diarrhea are not fully understood,
Cancer treatment-induced diarrhea affects a high percentage of patients with cancer that receive chemotherapy or radiation treatment. Widely used criteria for measuring treatment-induced diarrhea, such as the National Cancer Institute Common Toxicity Criteria, do not account for important
Diarrhea is one of the most common complaints in oncologic patients. Causes are multiple including bowel resection, infections, radiation and systemic anti-cancer treatments. In the latter case, the pathophysiology is partially elucidated and requires the etiology to be precisely identified :
This program used a case-study approach to discuss interventions that nurses can implement in their daily clinical environment to minimize cancer treatment-induced diarrhea. Manifestations of cancer treatment-induced diarrhea, medical treatment options, and nutritional interventions were covered.
OBJECTIVE
Randomized studies have suggested that sucralfate is effective in mitigating diarrhea during pelvic radiation therapy (RT). This North Central Cancer Treatment Group study was undertaken to confirm the antidiarrheal effect of sucralfate. Several other measures of bowel function were also
Irinotecan (CPT-11), a first-line chemotherapy for advanced colorectal cancer, causes serious diarrhea in patients receiving treatment. The underlying mechanism has been shown that the active metabolite of CPT-11, SN-38, is metabolized to the inactive metabolite SN-38 glucuronide (SN-38 G) during
OBJECTIVE
To evaluate and compare the influence of dietary elements on cancer progression, chemotherapy efficacy, and toxicity, particularly severe, late-onset diarrhea related to irinotecan (CPT-11) treatment.
METHODS
We used laboratory rats fed a standardized basal diet, Ward colon tumor, and
OBJECTIVE
To update and expand on previously published clinical practice guidelines for the treatment of cancer treatment-induced diarrhea.
METHODS
An expert multidisciplinary panel was convened to review the recent literature and discuss recommendations for updating the practice guidelines
OBJECTIVE
The effectiveness and improvement in quality of life (QOL) of a long-acting formulation of octreotide (LAR) administration for cancer patients, with chronic loperamide-refractory diarrhea not attributed to medical therapy, were investigated.
METHODS
Twenty-nine patients with chronic
OBJECTIVE
To assess the effectiveness of depot octreotide for the prevention of diarrhea during pelvic radiation therapy.
METHODS
Patients receiving pelvic radiation therapy (planned minimum dose, 45 Gy; 1.7 to 2.1 Gy daily) were eligible for the study. From May 10, 2002, through October 14, 2005,
Digestive complications are frequent dose-limiting side-effect of chemotherapy. Diarrhea and constipation can affect quality of life and alter optimum treatment efficacy. The incidence and the severity of these toxicities have to be systematically evaluated in order to provide specific curative and
OBJECTIVE
To describe possible new strategies for the prevention of CTID.
METHODS
Abstracts presented at oncology meetings, primary and secondary literature, trial protocols, and clinical experience.
CONCLUSIONS
Patients who have experienced an episode of diarrhea are at high risk for developing
OBJECTIVE
To describe the dietary and pharmacologic management of acute CTID.
METHODS
Primary and secondary literature, and clinical experience.
CONCLUSIONS
When dietary strategies do not work, or when patients present with grade 3/4 diarrhea, pharmacologic intervention is required. First-line